Medications for Exertional Angina

For patients with exertional angina—a type of stable angina triggered by physical activity or emotional stress—pharmacologic management focuses on reducing myocardial oxygen demand, improving coronary blood flow, and preventing disease progression. First-line therapy typically includes beta-blockers (e.g., metoprolol, bisoprolol), which lower heart rate, blood pressure, and contractility, thereby decreasing cardiac workload and oxygen consumption.

Nitrates—particularly short-acting sublingual nitroglycerin—are used acutely to relieve angina episodes by inducing coronary vasodilation and reducing preload. Long-acting nitrates (e.g., isosorbide mononitrate) may be prescribed for prophylaxis but are generally avoided as monotherapy due to tolerance development.

Calcium channel blockers (e.g., amlodipine, diltiazem) serve as alternatives or adjuncts—especially in patients with contraindications to beta-blockers or concomitant vasospastic components. They reduce afterload and coronary vasospasm while preserving or modestly increasing heart rate, depending on the agent class.

Antiplatelet therapy, most commonly low-dose aspirin, is routinely recommended to mitigate thrombotic risk in patients with established coronary artery disease. In select higher-risk individuals, dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor) may be considered following recent acute coronary syndrome or revascularization.

High-intensity statins (e.g., atorvastatin 40–80 mg or rosuvastatin 20–40 mg daily) are essential for lipid-lowering and plaque stabilization, regardless of baseline cholesterol levels. Additional agents—including ACE inhibitors or ARBs in patients with hypertension, diabetes, or left ventricular dysfunction—and sodium-glucose cotransporter-2 (SGLT2) inhibitors or GLP-1 receptor agonists in those with comorbid type 2 diabetes—are increasingly integrated into comprehensive cardiovascular risk reduction strategies.

Treatment selection must be individualized based on comorbidities, tolerability, drug interactions, and hemodynamic profile. All pharmacologic interventions should be coupled with lifestyle optimization—including smoking cessation, structured cardiac rehabilitation, dietary modification, and regular aerobic exercise—as foundational components of long-term management.